Detalhe da pesquisa
1.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
Gynecol Oncol
; 170: 172-178, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36706643
2.
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.
Proc Natl Acad Sci U S A
; 116(2): 619-624, 2019 01 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30584090
3.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A
; 116(45): 22730-22736, 2019 11 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31624127
4.
Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
Gynecol Oncol
; 158(3): 769-775, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32600791
5.
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Gynecol Oncol
; 156(2): 430-438, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31839338
6.
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Gynecol Oncol
; 155(1): 144-150, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31434613
7.
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Gynecol Oncol
; 153(1): 158-164, 2019 04.
Artigo
Inglês
| MEDLINE | ID: mdl-30630630
8.
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Gynecol Oncol
; 149(3): 585-591, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29572027
9.
Rapidly progressing ascites in a pregnancy with a massive fibroid: A case report and review of pseudo-Meigs syndrome.
Int J Gynaecol Obstet
; 2024 May 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38736303
10.
A simulation of diffractive liquid crystal smart window for privacy application.
Sci Rep
; 12(1): 11384, 2022 Jul 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35790764
11.
Highly Reliable Flexible Device with a Charge Compensation Layer.
ACS Appl Mater Interfaces
; 14(10): 12863-12872, 2022 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35234454
12.
Incidence and predictors of toxicity in the management of vulvar squamous cell carcinoma treated with radiation therapy.
Gynecol Oncol Rep
; 44: 101086, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36281250
13.
Effects of polyimide curing on image sticking behaviors of flexible displays.
Sci Rep
; 11(1): 21805, 2021 Nov 08.
Artigo
Inglês
| MEDLINE | ID: mdl-34750451
14.
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study.
Gynecol Oncol Rep
; 34: 100667, 2020 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-33204797
15.
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
Oncotarget
; 11(5): 560-570, 2020 Feb 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32082489
16.
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
Sci Rep
; 10(1): 973, 2020 01 22.
Artigo
Inglês
| MEDLINE | ID: mdl-31969666
17.
Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
Mol Oncol
; 14(3): 645-656, 2020 03.
Artigo
Inglês
| MEDLINE | ID: mdl-31891442
18.
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Front Oncol
; 10: 118, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32117765
19.
Photodynamic therapy with recombinant adenovirus AdmIL-12 enhances anti-tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model.
Immunology
; 124(4): 461-8, 2008 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-18397271
20.
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.
Gynecol Oncol Rep
; 25: 41-44, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29946554